The Capex Bet Demands Proof—Margin Compression Is Built In
H1 delivered 18.46% EBITDA margins and 88% capacity utilization, but management guided to 14–15% forward. The gap—over 300 basis points—is the story: capex depreciation and working capital drain, unproven against a mere ₹6 crore advance order book.
18.46%
Actual
14–15%
Management guidance
~300 bps
Capex depreciation + WC drag
Liotech Industries delivered a solid first half. H1 FY27 revenue of ₹33.64 crore generated EBITDA of ₹6.21 crore (18.46% margin) and PAT of ₹3.54 crore (10.51% margin). Demand is real: the company is running at 88% capacity utilization with an advance order book of ₹6+ crore. That's credible. But on the call, management contradicted its own result. When asked about the strong H1 margins, leadership said current EBITDA is 14%—not 18.46%—and guided to 14–15% forward. That gap, over 300 basis points lower than what just shipped, is the tension the quarter must resolve.
What management claimed vs. what holds up
Advance orders ₹6+ crore with 30-day execution
SupportedJune 2026 domestic purchase order ₹6.46 crore confirmed; order depth and customer traction evident
88% capacity utilization, nearly at max
SupportedCurrent 8 MT/day (12-hour shift); prior capacity 4 MT/day in FY25; Q&A confirms figure
EBITDA margin target 15–16% post-capex
ContradictedH1 actual 18.46% (₹6.21 Cr on ₹33.64 Cr); management cites 'current 14%' and targets only 14–15%, contradicting reported result
118% CAGR revenue growth in recent period
OverstatedNo YoY baseline disclosed; prior capacity 4 MT/day (FY25) now 8 MT/day; growth rate unsubstantiated by specific numbers
The margin contradiction is the fulcrum. Management cites loan repayment and IPO proceeds reducing interest burden as drivers of the strong H1 EBITDA. But looking forward, they guide to lower margins—attributing the step-down to capex depreciation and working capital drain. No detailed bridge was provided. Pressed on the gap, management held the line at 14–15% but offered no reconciliation of why H1's 18.46% is unsustainable. Either H1 was an outlier (possible if loan repayment and interest savings were temporary), or the forward guidance is conservative hedging. Neither inspires confidence in the capex payback thesis.
What changed on this call
Three material shifts from pre-IPO to post-IPO:
Pricing power: Post-IPO selling price increased ₹100 → ₹105 per unit (+5%). Management cites improved inquiries and brand traction from June 2026 listing.
Capex commitment: Company deploying ₹10 crore (machinery, facility modernization) on a 2.5x capacity expansion timeline of 1–2 months. ₹24.25 crore of ₹36.02 crore IPO proceeds deployed for machinery, loan repayment, and working capital. Benefits flagged for FY28.
Geographic and product expansion: From 9 states to planned 36-state rollout; 150+ SKUs; defense tender license investment (₹60 lakh); export expansion (South Africa, Gulf) flagged but unquantified.
These are not minor tweaks. The capex bet—more than 3x the quarterly EBITDA—is a leverage point. If it delivers on time and ramps to full utilization, margins recover and geographic expansion becomes viable. If it delays, demand softens post-expansion, or working capital strains mount, Liotech faces stranded capacity and prolonged margin pressure.
The bull-bear ledger
Strong near-term demand: 88% utilization and ₹6+ crore advance orders confirm market pull
Pricing power: 5% post-IPO increase accepted by customer base; TAM upside from residential, commercial, infrastructure sectors
First post-IPO earnings; IPO funds deployed credibly (machinery, debt paydown, working capital)
Capex bet on 2.5x capacity with no binding demand beyond ₹6 crore order book—execution risk material
Margin guidance (14–15% EBITDA forward) is 300+ bps below H1 actual; bridge unexplained; depreciation drag unquantified
Geographic concentration (9 of 36 states); 100% B2B model (dealers, distributors); customer concentration opaque
Defense tender contingency (₹60 lakh) and export revenue unquantified; execution timelines vague
Risks, ranked by how much they should concern a holder
Capex execution delay or cost overrun; stranded capacity post-expansion
High₹10 crore capex (almost 3x H1 EBITDA) with only ₹6+ crore advance orders to absorb new capacity. If ramp is slower than 2–3 months, ROI erodes and capex depreciation crushes margins into FY28.
Margin compression baked into guidance; depreciation and working capital drag unquantified
HighH1 EBITDA 18.46%; forward target 14–15%. No detailed bridge. If capex depreciation alone exceeds 200 bps, working capital becomes a residual. Miss on either could push margins into single digits.
Demand softness post-geographic expansion; customer concentration opaque
Medium9-to-36-state rollout is execution-intensive. 100% B2B model (dealers, distributors) with no large OEM contracts disclosed. Single customer loss or expansion margin bleed (new distributor support, logistics) could flatten growth.
Raw material (steel) price volatility; 5% pass-through threshold leaves company exposed
MediumCompany absorbs steel price changes up to 5%; passes through above. H1 saw firm prices, but upside surprise could compress margins 100+ bps if prices spike.
Defense tender qualification contingent; export revenue timing vague
Low₹60 lakh investment (0.18% of H1 revenue) is immaterial; upside if qualified. South Africa and Gulf exports flagged but unquantified; execution risk deferred to FY28 at earliest.
How the street is reading this
Liotech's stock stands at ₹104, down 57% from its all-time high of ₹244.15 but up 25% off the ₹83.53 low. The drawdown is steep, but context matters. The ATH was set during IPO-day euphoria in June 2026; the sharp decline since reflects the market repricing the capex bet and margin guidance downside against initial post-IPO optimism. The stock is trading above its 20-day (₹94.1) and 50-day (₹96.31) moving averages, suggesting it has found near-term support. RSI at 58.3 is neutral—neither oversold nor overbought—indicating the market is at an equilibrium of indecision.
Ownership is 71.22% promoter-held with zero FII and DII participation. That's typical for a fresh SME IPO but signals the absence of institutional conviction or accumulation. Bulk deal activity in mid-July 2026 shows mixed trading flows (NEO APEX, BONANZA, AIKYAM portfolio trades) but no clear insider accumulation or insider selling pressure near the highs. The quiet institutional absence and the stock's 57% drawdown from ATH suggest the market is waiting for execution proof: capex completion, margin stabilization, and ramp clarity over Q3 FY27 and Q4 FY27.
The debate
The honest read: Liotech is betting its IPO capital on a 2.5x capacity expansion with margin recovery to 14–15% EBITDA post-depreciation. That's not a step-change thesis; it's a steady-state SME playing the mid-tier architectural hardware consolidation wave. The quarter proves demand is real (88% utilization, pricing power, advance orders). But the margin contradiction—18.46% actual vs. 14–15% guided—betrays either operational headwinds management won't quantify or conservative hedging. Neither reads as confidence. Hold the stock through capex completion (expected Dec 2026–Jan 2027) and Q4 FY27 utilization data. If utilization stays above 85% and margins hold above 13% EBITDA post-capex, the thesis survives and re-rating follows. If capacity sits idle or margins compress below 12%, the capex ROI fails.
1 · Capex completion and machinery commissioning
Expected Dec 2026–Jan 2027. Delay or cost overrun is a red flag. Track facility inspection updates and capex deployment via investor communications and Q3 results.
2 · Post-capex utilization and margin recovery in Q4 FY27 results
The 300+ bps margin compression (18.46% → 14–15%) must reverse post-depreciation ramp. If H2 FY27 EBITDA margin falls below 12%, the capex thesis fails and the stock re-rates lower.
3 · Advance order ramp and geographic expansion traction
9-to-36-state rollout execution and export revenue (South Africa, Gulf) must be quantified by Q1 FY28 results. Without binding orders, new capacity sits idle and ROI erodes.
Liotech's H1 delivered strong operational metrics (demand, pricing power, utilization) but left the fundamental question open: Can a small capex-dependent SME execute a 2.5x capacity bet and maintain 14–15% EBITDA margins? The stock is priced for skepticism (down 57% from ATH, zero institutional ownership), which is fair. Accumulate cautiously if capex completes on time and Q4 margins hold; exit if H2 utilization or margins deteriorate. The single number to track: post-capex EBITDA margin in Q4 FY27. Everything else follows from that.
Informational and educational content only. Not investment advice.